Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents

Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents

Penzak, Scott R.; Cohen, Lawrence J.; Jann, Michael W.

Springer International Publishing AG

04/2018

601

Mole

Inglês

9783319802343

15 a 20 dias

Descrição não disponível.
Section 1. General Pharmacokinetic and Pharmacodynamic Principles of
Psychopharmacological Agents.- 1. Pharmacokinetic Properties.- 2. Pharmacodynamic
Properties.- 3. PET Scan and Other Biomarkers.- 4. Population
Pharmacokinetics.- 5. Drug Transporters (esp. Blood Brain Barrier).- 6. Pharmacogenomics.-
Section 2. Clinical Pharmacokinetics and Pharmacodynamics of
Psychopharmacological Drug Classes.- 7. Antipsychotics - oral typical agents,
oral atypical agents, and long-acting injectable (LAI) antipsychotics.- 8. Mood
Stabilizers.- 9. Antidepressants - tricyclics, selective serotonergic reuptake
inhibitors, serotonergic noradrenergic reuptake inhibitors, monoamine oxidase
inhibitors, and other antidepressants.- 10. Benzodiazepines and Other Sedative
Hypnotics/Anxiolytics.- 11. Opioid Analgesics.- 12. Stimulants and Other
Non-Stimulants for ADHD.- 13. Cholinesterase Inhibitors and Other Antidementa
Agents.- 14. Anti-Addiction Agents.- 15. Anesthetics.- Section 3. Clinically
Significant Drug Interactions With Psychopharmacological Agents.- 16.
Antipsychotics.- 17. Mood Stabilizers.- 18. Antidepressants.- 19.
Benzodiazepines and Other Sedative Hypnotics/Anxiolytics.- 20. Opioid
Analgesics.- 21. Stimulants and Other Non-Stimulants for ADHD.- 22. Cholinesterase
Inhibitors and Other Antidementa Agents.- 23. Anti-Addiction Agents.- 24.
Anesthetics.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Acetylaldehyde Hydrogenase;Atypical;Candidate Gene;Cell Membrane;Central Nervous System;CYP2C19 Enzyme;Emax Model;Grapefruit Juice;Immediate-Release Formulation;Immunosuppressants;Inhibitor;Kappa Opiate Receptor;Modeling Analysis;Muscle Relaxant;N-Methyl-D-Aspartate (NMDA) Receptor;Non-Steroid Anti-inflammatory Drugs (NSAIDs);Prophylaxis;Protein Binding Interactions;Radiotracer;Receptor Systems